Number of shares and votes in Medivir

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed as a result of the issue of 3,968,841 class B shares, which was carried out in February 2018.

Today, the last trading day of the month, there are in total 24,287,818 shares in Medivir, of which 474,769 class A shares and 23,813,049 class B shares, totaling 28,560,739 votes. As previously announced, all class A shares in Medivir will be converted to class B shares.
  

For further information, please contact:
Christine Lind, CEO Medivir AB, phone: +46 (0)8 407 4641
Erik Björk, CFO Medivir AB, phone: +46 (0)72 228 2831

This is information that Medivir AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 16.00 CET on 28 February 2018.

About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links